LMR GEORGETTE PMHNP BOARD EXAM REVIEW PDF ACTUAL
EXAM 2026/2027 - HIGH-YIELD BOARD REVIEW QUESTIONS WITH
ANSWERS - PASS GUARANTEED - A+ GRADED
170 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Apply advanced neurobiological and psychopharmacological principles to complex clinical scenarios
2 Integrate evidence-based psychotherapeutic modalities and ethical-legal frameworks into holistic care
3 Demonstrate proficiency in differential diagnosis and treatment planning for diverse psychiatric
presentations
4 LMR Georgette PMHNP Board Exam Review PDF Actual Exam 2026
5 2027
6 High
7 Yield Board Review Questions with Answers
8 Pass Guaranteed
9 A+ Graded
10 Foundations of Psychiatric-Mental Health Nurse Practitioner (PMHNP) Board Review
11 Applied Psychiatric-Mental Health Nurse Practitioner (PMHNP) Board Review
12 Advanced Psychiatric-Mental Health Nurse Practitioner (PMHNP) Board Review
13 Psychiatric-Mental Health Nurse Practitioner (PMHNP) Board Review Review
Page 1
,Q1 APPLY ADVANCED NEUROBIOLOGICAL AND PSYCHOPHARMACOLOGICAL PRINCIPLES
TO COMPLEX CLINICAL SCENARIOS
A patient with treatment-resistant depression has failed adequate trials of two
SSRIs and one SNRI. Which augmentation strategy is most strongly supported by
current evidence for rapid response in urgent clinical situations?
A. Adding aripiprazole
B. Adding low-dose olanzapine
C. Intravenous ketamine CORRECT
D. Switching to a monoamine oxidase inhibitor
RATIONALE: Intravenous ketamine has demonstrated rapid antidepressant effects, often within
hours, making it the preferred choice for urgent cases. Aripiprazole and olanzapine are effective
but take weeks for full effect. MAOIs are effective but have a delayed onset and significant
dietary restrictions.
Q2 APPLY ADVANCED NEUROBIOLOGICAL AND PSYCHOPHARMACOLOGICAL PRINCIPLES
TO COMPLEX CLINICAL SCENARIOS
Which of the following best explains the mechanism of action of brexpiprazole in
treating schizophrenia?
A. Full D2 receptor agonism with 5-HT2A antagonism
B. Partial D2 receptor agonism with 5-HT1A agonism and 5-HT2A antagonism CORRECT
C. Selective D3 receptor antagonism with no affinity for 5-HT receptors
D. Irreversible monoamine oxidase inhibition
RATIONALE: Brexpiprazole is a partial D2 agonist, which stabilizes dopamine tone, and also acts
as a 5-HT1A agonist and 5-HT2A antagonist, contributing to its efficacy and lower extrapyramidal
side effects. It does not irreversibly inhibit MAO, and its affinity for D3 is not its primary
mechanism.
Page 2
,Q3 APPLY ADVANCED NEUROBIOLOGICAL AND PSYCHOPHARMACOLOGICAL PRINCIPLES
TO COMPLEX CLINICAL SCENARIOS
A 30-year-old patient presents with recurrent, intrusive thoughts of contamination
and compulsive hand washing. The PMHNP considers exposure and response
prevention (ERP). Which principle is central to ERP's effectiveness?
A. Gradual exposure to feared stimuli while preventing compulsive rituals CORRECT
B. Cognitive restructuring to eliminate intrusive thoughts
C. Systematic desensitization using relaxation techniques alone
D. Aversive conditioning to reduce anxiety
RATIONALE: ERP involves exposing the patient to anxiety-provoking stimuli while blocking the
compulsive response, leading to habituation and extinction. Cognitive restructuring alone is less
effective for OCD. Systematic desensitization without response prevention is not the core.
Aversive conditioning is not used.
Q4 APPLY ADVANCED NEUROBIOLOGICAL AND PSYCHOPHARMACOLOGICAL PRINCIPLES
TO COMPLEX CLINICAL SCENARIOS
A patient with bipolar I disorder is stabilized on lithium but presents with a new
prescription for lisinopril for hypertension. What is the most significant concern?
A. Increased risk of serotonin syndrome
B. Elevated lithium levels due to decreased renal clearance CORRECT
C. Reduced antihypertensive efficacy
D. Increased risk of extrapyramidal symptoms
RATIONALE: ACE inhibitors like lisinopril can decrease glomerular filtration and sodium
reabsorption, leading to reduced lithium clearance and potentially toxic lithium levels. Serotonin
syndrome is not associated with this combination. The other options are not primary concerns.
Page 3
, Q5 APPLY ADVANCED NEUROBIOLOGICAL AND PSYCHOPHARMACOLOGICAL PRINCIPLES
TO COMPLEX CLINICAL SCENARIOS
Which of the following is the most appropriate first-line treatment for a patient with
moderate alcohol use disorder who has a goal of abstinence and no
contraindications?
A. Naltrexone CORRECT
B. Disulfiram
C. Acamprosate
D. Gabapentin
RATIONALE: Naltrexone is a first-line medication for alcohol use disorder, reducing craving and
relapse, and is recommended as initial therapy. Disulfiram is used but adherence is poor and it is
not first-line. Acamprosate is also first-line but often preferred in patients with liver disease.
Gabapentin is off-label and less established.
Q6 APPLY ADVANCED NEUROBIOLOGICAL AND PSYCHOPHARMACOLOGICAL PRINCIPLES
TO COMPLEX CLINICAL SCENARIOS
A patient with generalized anxiety disorder has not responded to an adequate trial
of sertraline. The PMHNP considers switching to a serotonin-norepinephrine
reuptake inhibitor (SNRI). Which SNRI is FDA-approved for GAD?
A. Desvenlafaxine
B. Venlafaxine
C. Duloxetine CORRECT
D. Levomilnacipran
RATIONALE: Duloxetine is FDA-approved for generalized anxiety disorder, whereas venlafaxine
is approved but often considered first-line; however, the question asks for an SNRI, and
duloxetine is specifically approved for GAD. Desvenlafaxine is approved for major depressive
disorder but not GAD. Levomilnacipran is approved for MDD only.
Page 4
EXAM 2026/2027 - HIGH-YIELD BOARD REVIEW QUESTIONS WITH
ANSWERS - PASS GUARANTEED - A+ GRADED
170 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Apply advanced neurobiological and psychopharmacological principles to complex clinical scenarios
2 Integrate evidence-based psychotherapeutic modalities and ethical-legal frameworks into holistic care
3 Demonstrate proficiency in differential diagnosis and treatment planning for diverse psychiatric
presentations
4 LMR Georgette PMHNP Board Exam Review PDF Actual Exam 2026
5 2027
6 High
7 Yield Board Review Questions with Answers
8 Pass Guaranteed
9 A+ Graded
10 Foundations of Psychiatric-Mental Health Nurse Practitioner (PMHNP) Board Review
11 Applied Psychiatric-Mental Health Nurse Practitioner (PMHNP) Board Review
12 Advanced Psychiatric-Mental Health Nurse Practitioner (PMHNP) Board Review
13 Psychiatric-Mental Health Nurse Practitioner (PMHNP) Board Review Review
Page 1
,Q1 APPLY ADVANCED NEUROBIOLOGICAL AND PSYCHOPHARMACOLOGICAL PRINCIPLES
TO COMPLEX CLINICAL SCENARIOS
A patient with treatment-resistant depression has failed adequate trials of two
SSRIs and one SNRI. Which augmentation strategy is most strongly supported by
current evidence for rapid response in urgent clinical situations?
A. Adding aripiprazole
B. Adding low-dose olanzapine
C. Intravenous ketamine CORRECT
D. Switching to a monoamine oxidase inhibitor
RATIONALE: Intravenous ketamine has demonstrated rapid antidepressant effects, often within
hours, making it the preferred choice for urgent cases. Aripiprazole and olanzapine are effective
but take weeks for full effect. MAOIs are effective but have a delayed onset and significant
dietary restrictions.
Q2 APPLY ADVANCED NEUROBIOLOGICAL AND PSYCHOPHARMACOLOGICAL PRINCIPLES
TO COMPLEX CLINICAL SCENARIOS
Which of the following best explains the mechanism of action of brexpiprazole in
treating schizophrenia?
A. Full D2 receptor agonism with 5-HT2A antagonism
B. Partial D2 receptor agonism with 5-HT1A agonism and 5-HT2A antagonism CORRECT
C. Selective D3 receptor antagonism with no affinity for 5-HT receptors
D. Irreversible monoamine oxidase inhibition
RATIONALE: Brexpiprazole is a partial D2 agonist, which stabilizes dopamine tone, and also acts
as a 5-HT1A agonist and 5-HT2A antagonist, contributing to its efficacy and lower extrapyramidal
side effects. It does not irreversibly inhibit MAO, and its affinity for D3 is not its primary
mechanism.
Page 2
,Q3 APPLY ADVANCED NEUROBIOLOGICAL AND PSYCHOPHARMACOLOGICAL PRINCIPLES
TO COMPLEX CLINICAL SCENARIOS
A 30-year-old patient presents with recurrent, intrusive thoughts of contamination
and compulsive hand washing. The PMHNP considers exposure and response
prevention (ERP). Which principle is central to ERP's effectiveness?
A. Gradual exposure to feared stimuli while preventing compulsive rituals CORRECT
B. Cognitive restructuring to eliminate intrusive thoughts
C. Systematic desensitization using relaxation techniques alone
D. Aversive conditioning to reduce anxiety
RATIONALE: ERP involves exposing the patient to anxiety-provoking stimuli while blocking the
compulsive response, leading to habituation and extinction. Cognitive restructuring alone is less
effective for OCD. Systematic desensitization without response prevention is not the core.
Aversive conditioning is not used.
Q4 APPLY ADVANCED NEUROBIOLOGICAL AND PSYCHOPHARMACOLOGICAL PRINCIPLES
TO COMPLEX CLINICAL SCENARIOS
A patient with bipolar I disorder is stabilized on lithium but presents with a new
prescription for lisinopril for hypertension. What is the most significant concern?
A. Increased risk of serotonin syndrome
B. Elevated lithium levels due to decreased renal clearance CORRECT
C. Reduced antihypertensive efficacy
D. Increased risk of extrapyramidal symptoms
RATIONALE: ACE inhibitors like lisinopril can decrease glomerular filtration and sodium
reabsorption, leading to reduced lithium clearance and potentially toxic lithium levels. Serotonin
syndrome is not associated with this combination. The other options are not primary concerns.
Page 3
, Q5 APPLY ADVANCED NEUROBIOLOGICAL AND PSYCHOPHARMACOLOGICAL PRINCIPLES
TO COMPLEX CLINICAL SCENARIOS
Which of the following is the most appropriate first-line treatment for a patient with
moderate alcohol use disorder who has a goal of abstinence and no
contraindications?
A. Naltrexone CORRECT
B. Disulfiram
C. Acamprosate
D. Gabapentin
RATIONALE: Naltrexone is a first-line medication for alcohol use disorder, reducing craving and
relapse, and is recommended as initial therapy. Disulfiram is used but adherence is poor and it is
not first-line. Acamprosate is also first-line but often preferred in patients with liver disease.
Gabapentin is off-label and less established.
Q6 APPLY ADVANCED NEUROBIOLOGICAL AND PSYCHOPHARMACOLOGICAL PRINCIPLES
TO COMPLEX CLINICAL SCENARIOS
A patient with generalized anxiety disorder has not responded to an adequate trial
of sertraline. The PMHNP considers switching to a serotonin-norepinephrine
reuptake inhibitor (SNRI). Which SNRI is FDA-approved for GAD?
A. Desvenlafaxine
B. Venlafaxine
C. Duloxetine CORRECT
D. Levomilnacipran
RATIONALE: Duloxetine is FDA-approved for generalized anxiety disorder, whereas venlafaxine
is approved but often considered first-line; however, the question asks for an SNRI, and
duloxetine is specifically approved for GAD. Desvenlafaxine is approved for major depressive
disorder but not GAD. Levomilnacipran is approved for MDD only.
Page 4
